Understanding airway wall remodeling in asthma: a basis for improvements in therapy?
Current strategies for the management of asthma focus on suppressing airway inflammation. Other characteristic features of human asthma, such as airway hyperreactivity and the structural changes collectively referred to as airway remodeling, are largely ignored in existing guidelines for monitoring the effectiveness of treatment. Evidence is accumulating that pharmacologic therapy targeting airway wall remodeling may be valuable in treating asthma. However, development of appropriate therapeutic agents will require a better understanding of the pathogenesis of remodeling, which appears to be regulated by a variety of cytokines and growth factors produced by inflammatory, epithelial, and stromal cells. Furthermore, testing the effectiveness of novel agents that specifically target the process of remodeling will require appropriate experimental models, but most currently available animal models of asthma have major limitations. A recently described murine model of chronic human asthma offers considerable potential for dissection of the mechanisms of airway wall remodeling, as well as for investigation of the therapeutic potential of drugs that can modulate chronic inflammation and remodeling.
Kumar
R K
RK
Inflammation Research Unit, School of Pathology, The University of New South Wales, Sydney, Australia 2052. R.Kumar@unsw.edu.au
D000403:Airway Resistance / Q000502:physiology*; D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology*; D016207:Cytokines / Q000494:pharmacology; D004195:Disease Models, Animal; D006133:Growth Substances / Q000494:pharmacology; D006801:Humans; D007249:Inflammation / Q000503:physiopathology*; D051379:Mice
D016207:Cytokines; D006133:Growth Substances